Two biotech buys
Two biotech buys
About this video
Rory Hunter, a representative of SG Hiscock & Company, sheds light on the potential of investment in Australian biotech companies. He posits that these companies are ready for investment, particularly those involved in phase three of clinical assets. Given the impending rate cuts and the S&P 500's historical performance during rate-cutting cycles, Rory points out that healthcare, specifically medtech and biotech, typically outperforms other sectors.
Rory's focus specifically on phase three clinical assets underscores the unique transitional opportunity these firms present, moving from safety and efficacy data towards the commercialization phase. He cites Immutep (ASX: IMM) as an example of a company in this phase, envisaging an astronomical share price if they successfully launch their products to the market. He encourages investors to exercise caution and understand the commercialization opportunities before making decisions.
Contrarily, Rory notes the disappointing performance in the medtech sector, attributing it to valuation multiple downgrades and the unsuccessful actualization of growth ambitions. He suggests this has resulted from a 'pandemic hangover' and the subsequent re-allocation of resources towards pandemic-related backlogs. Despite this, Rory sees potential value in small medtech firms such as dimerix (ASX: DXB) in the current market cycle and affirms his intention of buying undervalued stocks.